search
Back to results

Dietary Potassium Liberalization in Pre-Dialysis Patients (DK-LIB)

Primary Purpose

Chronic Kidney Disease, Hyperkalemia

Status
Not yet recruiting
Phase
Not Applicable
Locations
Canada
Study Type
Interventional
Intervention
Liberalized dietary potassium via fruits and vegetables
Standard dietary potassium restriction
Sponsored by
University of Manitoba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Chronic Kidney Disease focused on measuring Potassium, Nutrition

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Male or female, aged 18 years or above
  • Participants who have an estimated glomerular filtration rate between 15 and 45 ml/min/1.73m2
  • Serum potassium concentration between 4.9 and 5.5 milliequivalent (mEq)/L
  • Hemoglobin A1c < 11%
  • Are registered in the multidisciplinary nephrology clinic in Winnipeg
  • Able to communicate in English and provide written informed consent

Exclusion Criteria:

  • Serum potassium concentration > 5.4 mEq/L, anuria, dialysis, or acute kidney injury failure in the 6 months prior to screening
  • Chronic obstructive pulmonary disease that requires the participant to be on oxygen
  • New York Heart Association Class 3-4 Heart failure symptoms or heart, liver or renal transplant
  • A myocardial infarction or stroke within the last 6 months
  • Unable to consume study treatments or control, such as swallowing or gastro-intestinal issues
  • Currently on potassium binding therapy
  • In the opinion of the investigator any medical condition, uncontrolled systemic disease or concurrent illness that would decrease the study compliance or jeopardize the safety of the participant
  • Female participant who is pregnant or lactating

Sites / Locations

  • Seven Oaks General Hospital Chronic Disease Innovation Centre
  • Health Sciences Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Liberalized dietary potassium and then restricted potassium via fruit and vegetables

Restricted dietary potassium and then liberalized potassium via fruit and vegetables

Arm Description

Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2-week run-in and liberalized potassium treatment period, then cross-over to the restricted potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional Coronavirus disease (COVID)-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet.

Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2 week run-in and then start receiving a restricted potassium treatment period, then cross-over to the liberalized potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional COVID-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet

Outcomes

Primary Outcome Measures

Change in serum potassium concentrations between treatments
Serum potassium at the end of the liberalize dietary potassium period compared to the end of restricted dietary potassium period

Secondary Outcome Measures

Change in physical function related quality of life between treatments
Participants will complete the SF-12 physical component score of the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire.
Change in urinary sodium between treatments
Total sodium concentration in mmol/L
Change in urinary potassium between treatments
total potassium concentration in mmol/L
Urinary albumin to creatinine Ratio
calculated by dividing urinary albumin concentration in milligrams by urinary creatinine concentration in grams
Hemoglobin A1c
Measure of glycosylated hemoglobin, hemoglobin A1c, expressed as a percentage
Systolic blood pressure
Blood pressure will be measured in triplicate using a validated blood pressure monitor following Kidney Disease: Improving Global Outcomes (KDIGO) 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
Diastolic blood pressure
Blood pressure will be measured in triplicate using a validated blood pressure monitor following KDIGO 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
Five repetition chair stand time
Assessing physical functionality by asking participant to sit with arms folded in a chair and then stand up and sit down 5 times as fast as they can, time to complete is recorded.

Full Information

First Posted
October 12, 2021
Last Updated
July 17, 2023
Sponsor
University of Manitoba
Collaborators
Dalhousie University
search

1. Study Identification

Unique Protocol Identification Number
NCT05090865
Brief Title
Dietary Potassium Liberalization in Pre-Dialysis Patients
Acronym
DK-LIB
Official Title
Dietary Potassium Liberalization With Fruit and Vegetables Versus Potassium Restriction in People With Chronic Kidney Disease (DK-Lib CKD) Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 15, 2023 (Anticipated)
Primary Completion Date
April 1, 2024 (Anticipated)
Study Completion Date
October 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of Manitoba
Collaborators
Dalhousie University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The study will look at the impact of the potassium content in fruits and vegetables, on serum potassium concentrations in people with Chronic Kidney Disease (CKD) using a randomized crossover design. Participants will receive home delivery of fruit and vegetables with either higher or lower potassium content in a random order. Clinical chemistry markers from blood and urine samples, blood pressure, physical functioning and health related quality of life will be assessed throughout the duration of the trial. This study will also measure their physical functioning, using a chair stand test. The results of this study could change the dietary recommendations for people with CKD related to potassium.
Detailed Description
The kidney is a primary site of potassium regulation in the body. Hyperkalemia, elevated serum potassium, occurs in approximately 10% of patients with chronic kidney disease (CKD) and is associated with elevated all-cause mortality. To minimize the risk of hyperkalemia, individuals with CKD are told to restrict dietary potassium. This recommendation is based on very-low quality evidence. Dietary potassium restrictions can negatively impact quality of life, and may put participants at risk of nutritional deficiencies so they should be based on good quality evidence. There is a need for high quality randomized controlled trials investigating the impact of dietary potassium modification on serum potassium concentrations in people with CKD. This trial will evaluate the impact and safety of dietary potassium liberalization using fruit and vegetables on serum potassium concentrations in people with CKD. In this 16-week study, the investigators will test if changing the amount of potassium people with CKD are eating with fruits and vegetables changes the amount of potassium in their blood. The investigators will do this by providing people with fruits and vegetables that are either high or low in potassium for a period 6 weeks. Then these same participants will be provided with fruits and vegetables that they didn't receive in the first 6 weeks, for 6 weeks in what is called a randomized crossover design. In a randomized crossover design everyone gets both treatments, but the order they get them in is chosen at random, like a coin toss. Thirty participants, will be recruited to this study. The investigators will measure blood potassium during the study and see if it changes due to the change in potassium in the fruit and vegetables provided. The investigators think that changing the amount of potassium that participants eat through fruit and vegetables will not lead to a different level of potassium in the participants blood, and that having higher potassium fruit and vegetables in the diet may lead to an increase in the participants quality of life. This study's results could change the dietary recommendation given to people living CKD and potentially allow them to eat a greater variety of food.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Chronic Kidney Disease, Hyperkalemia
Keywords
Potassium, Nutrition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Liberalized dietary potassium and then restricted potassium via fruit and vegetables
Arm Type
Other
Arm Description
Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2-week run-in and liberalized potassium treatment period, then cross-over to the restricted potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional Coronavirus disease (COVID)-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet.
Arm Title
Restricted dietary potassium and then liberalized potassium via fruit and vegetables
Arm Type
Other
Arm Description
Participants will receive weekly supplementation of higher potassium fruit and vegetables via grocery home delivery during the liberalized dietary potassium 2 week run-in and then start receiving a restricted potassium treatment period, then cross-over to the liberalized potassium treatment period following a 2-week washout period. Participants will receive a 30-60 minute dietary counseling session in the first week of each treatment period from a registered dietitian (RD), either in person or via videoconference, depending on regional COVID-19 restrictions and participant preference, which will outline the concepts of the dietary intervention. The RD will also recommend the best ways to prepare and include the fruit and vegetables into the participant's current diet
Intervention Type
Dietary Supplement
Intervention Name(s)
Liberalized dietary potassium via fruits and vegetables
Intervention Description
On the liberalized dietary potassium intervention, participants will receive groceries delivered to their houses that contain potassium rich fruit and vegetables, that contain more than 200 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 1500 mg of potassium a day from delivered fruit and vegetables, and a daily dietary potassium intake of 3500 mg.
Intervention Type
Dietary Supplement
Intervention Name(s)
Standard dietary potassium restriction
Intervention Description
Participants will receive weekly supplementation of lower potassium fruit and vegetables, that deliver less than 125 mg of potassium per typical serving. Participants will be instructed to incorporate the fruit and vegetables into their diet targeting a daily intake of 500 mg of K a day from the box, and a daily dietary K intake < 2000 mg. Participants will receive counselling from a registered dietician (RD) to reinforce the potassium restriction.
Primary Outcome Measure Information:
Title
Change in serum potassium concentrations between treatments
Description
Serum potassium at the end of the liberalize dietary potassium period compared to the end of restricted dietary potassium period
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Secondary Outcome Measure Information:
Title
Change in physical function related quality of life between treatments
Description
Participants will complete the SF-12 physical component score of the Kidney Disease Quality of Life Short Form (KDQOL-SF) questionnaire.
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Title
Change in urinary sodium between treatments
Description
Total sodium concentration in mmol/L
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Title
Change in urinary potassium between treatments
Description
total potassium concentration in mmol/L
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Title
Urinary albumin to creatinine Ratio
Description
calculated by dividing urinary albumin concentration in milligrams by urinary creatinine concentration in grams
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Title
Hemoglobin A1c
Description
Measure of glycosylated hemoglobin, hemoglobin A1c, expressed as a percentage
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Title
Systolic blood pressure
Description
Blood pressure will be measured in triplicate using a validated blood pressure monitor following Kidney Disease: Improving Global Outcomes (KDIGO) 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Title
Diastolic blood pressure
Description
Blood pressure will be measured in triplicate using a validated blood pressure monitor following KDIGO 2021 measurement guidelines, the average of the 2nd and 3rd measurements will be recorded.
Time Frame
between endpoints of each experimental period (week 8 to week 16)
Title
Five repetition chair stand time
Description
Assessing physical functionality by asking participant to sit with arms folded in a chair and then stand up and sit down 5 times as fast as they can, time to complete is recorded.
Time Frame
between endpoints of each experimental period (week 8 to week 16)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female, aged 18 years or above Participants who have an estimated glomerular filtration rate between 15 and 45 ml/min/1.73m2 Serum potassium concentration between 4.9 and 5.5 milliequivalent (mEq)/L Hemoglobin A1c < 11% Are registered in the multidisciplinary nephrology clinic in Winnipeg Able to communicate in English and provide written informed consent Exclusion Criteria: Serum potassium concentration > 5.4 mEq/L, anuria, dialysis, or acute kidney injury failure in the 6 months prior to screening Chronic obstructive pulmonary disease that requires the participant to be on oxygen New York Heart Association Class 3-4 Heart failure symptoms or heart, liver or renal transplant A myocardial infarction or stroke within the last 6 months Unable to consume study treatments or control, such as swallowing or gastro-intestinal issues Currently on potassium binding therapy In the opinion of the investigator any medical condition, uncontrolled systemic disease or concurrent illness that would decrease the study compliance or jeopardize the safety of the participant Female participant who is pregnant or lactating
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Dylan Mackay, PhD
Phone
2042723119
Email
dylan.mackay@umanitoba.ca
First Name & Middle Initial & Last Name or Official Title & Degree
Rebecca Mollard, PhD
Email
rmollard@sogh.mb.ca
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Dylan Mackay, PhD
Organizational Affiliation
University of Manitoba
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seven Oaks General Hospital Chronic Disease Innovation Centre
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R2V 3M3
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rebecca Mollard, PhD
Email
rmollard@sogh.mb.ca
First Name & Middle Initial & Last Name & Degree
Dylan Mackay, PhD
First Name & Middle Initial & Last Name & Degree
Navdeep Tangri, MD, PhD
Facility Name
Health Sciences Centre
City
Winnipeg
State/Province
Manitoba
ZIP/Postal Code
R3A 1R9
Country
Canada
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Jay Hingwala, MD
Phone
204-787-3863
Email
jhingwala@hsc.mb.ca

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
De-identified individual participant data (IPD)may be placed in a repository if required by a journal for publication purposes. De-identified IPD may also be requested from the principle investigator.
IPD Sharing Time Frame
Data will become available following the publication of the primary results manuscript.
IPD Sharing Access Criteria
De-identified IPD may also be requested from the principle investigator upon reasonable request.

Learn more about this trial

Dietary Potassium Liberalization in Pre-Dialysis Patients

We'll reach out to this number within 24 hrs